Atrial fibrillation does not directly add body fat the way a sluggish thyroid or a calorie surplus does. Instead, the weight gain many people notice after an AF diagnosis comes through a tangle of indirect routes: medications prescribed for the condition, a sharp drop in physical activity driven partly by fear, fluid shifts from a heart that pumps less efficiently, and a biological feedback loop between heart-fat deposits and the arrhythmia itself. Untangling which pathway is responsible matters, because each one calls for a different response.
Medications That Tip the Scale
Two of the most commonly prescribed drug classes for atrial fibrillation have well-documented effects on body weight, and they often get overlooked as the culprit behind post-diagnosis weight gain.
Beta-blockers are a frontline tool for slowing a racing heart rate during AF episodes. They work well for that purpose, but they also dial down your resting metabolic rate by roughly ten percent. Across clinical trials that tracked weight changes, beta-blockers were linked to an average gain of about 1.2 kilograms, with some patients gaining more than three kilograms.1PubMed. Use of beta-blockers in obesity hypertension: potential role of weight gain That might sound modest, but a metabolic rate drop of ten percent adds up over months and years, especially if you were already sedentary before starting the medication. You burn fewer calories at rest, during sleep, and during light daily movement, and unless you consciously eat less or move more, the math tilts toward gradual gain.
Amiodarone, a powerful rhythm-control drug often reserved for AF that doesn’t respond to simpler treatments, carries a different risk. It contains a large amount of iodine and can disrupt thyroid function in both directions. In regions where dietary iodine is already sufficient, amiodarone tends to push the thyroid toward underactivity, a condition called amiodarone-induced hypothyroidism.2Journal of Intensive Care Medicine. Amiodarone-induced thyroid dysfunction An underactive thyroid slows metabolism, promotes fluid retention, and makes weight gain almost inevitable unless the problem is caught and treated. Many patients on long-term amiodarone have their thyroid checked periodically, but the connection between a new AF medication and unexplained weight gain isn’t always obvious at first.
Other medications used alongside AF treatment can contribute too. Corticosteroids prescribed for related inflammation, certain calcium channel blockers, and even the stress of managing a chronic condition (which can increase cortisol) all nudge weight upward. If you’ve gained weight since your AF diagnosis, reviewing your full medication list with your prescriber is a practical first step.
Exercise Avoidance and the Fear Factor
People living with atrial fibrillation tend to be far less physically active than guidelines recommend, and the shortfall is striking. One study measuring activity levels found that most adults with AF fell well below the global recommendation for moderate-to-vigorous physical activity, logging a median of only about 60 to 120 minutes per week instead of the recommended 150.3Journal of Cardiopulmonary Rehabilitation and Prevention. Sex Differences in Physical Activity Levels and Sitting Time in Patients With Atrial Fibrillation Daily sitting time hovered around five and a half to six hours. The gap between what these patients do and what would help them is significant enough to contribute meaningfully to weight gain over time.
Part of this inactivity is physical. AF episodes can cause palpitations, breathlessness, dizziness, and fatigue, which make exercise genuinely uncomfortable or frightening. But a large part is psychological. Research into the fear-avoidance pattern in AF patients describes a cycle where anxiety about triggering an episode leads to catastrophic thinking (“if I exercise, my heart could stop”), which leads to avoidance, which leads to deconditioning, depression, and lower quality of life.4PubMed Central. Addressing exercise phobia in atrial fibrillation patients post-radiofrequency ablation: a nursing perspective Even after procedures like ablation, which often eliminate or dramatically reduce AF episodes, patients can remain afraid to exercise. The fear outlasts the arrhythmia.
The irony is that moderate exercise is one of the strongest tools for managing AF and preventing weight gain. But the condition itself, and the emotional response to it, builds a wall between the patient and the activity that would help most. Breaking through that wall usually requires structured cardiac rehabilitation or at least explicit reassurance from a cardiologist that exercise is safe within certain parameters. Without that guidance, the default for many people is to do less, sit more, and watch the scale drift upward.
Fluid Retention and the Heart’s Pump Problem
When the upper chambers of the heart fibrillate instead of contracting rhythmically, the heart’s overall pumping efficiency drops. This is especially pronounced in people whose AF is persistent or who also have some degree of heart failure. A less efficient heart means the kidneys receive less blood flow, which triggers a cascade of hormonal signals telling the body to hold onto sodium and water. The result is fluid retention, which shows up on the scale as weight gain even though no fat has been added.
This kind of weight gain can appear quickly, sometimes a few pounds in just days, and tends to concentrate in the ankles, lower legs, and abdomen. It responds to diuretics and improved rate control rather than to dietary changes alone. If you notice rapid weight gain along with swelling, shortness of breath when lying flat, or worsening fatigue, that’s a sign the fluid pathway is at work and warrants prompt medical attention. Tracking your weight daily at the same time can help you and your care team spot fluid buildup early.
The Two-Way Street Between Obesity and AF
This is where the relationship between AF and weight gain gets genuinely complicated, because the causation runs in both directions. Obesity is one of the strongest known risk factors for developing AF in the first place, but the biological changes AF sets in motion can also make it harder to lose weight once you have it.
The obesity-to-AF direction is well documented. As body weight increases, the left upper chamber of the heart enlarges, its walls develop more scar tissue (fibrosis), and the electrical signals that coordinate heartbeats slow down and become more erratic.5PubMed. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation These structural and electrical changes create the conditions under which AF can start and sustain itself. In studies tracking progressive weight gain, each step upward in weight was associated with more fibrosis, more inflammatory infiltrates, and a greater tendency toward both triggered and persistent AF episodes.6PubMed. Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity
The AF-to-obesity direction is less studied but clinically real. Once AF develops, the medication effects and activity avoidance described earlier promote weight gain. Increased body weight then worsens the atrial remodeling that sustains AF, which leads to more symptoms, more medication, even less activity, and further weight gain. This feedback loop can feel relentless, and it explains why many patients feel like they’re gaining weight “because of AF” even though the arrhythmia itself isn’t directly adding fat cells. The condition creates the circumstances under which gaining weight becomes the path of least resistance.
The Role of Epicardial Fat
One of the more striking discoveries in AF research over the past decade is the role of epicardial adipose tissue, the layer of fat that sits directly on the surface of the heart. Unlike the fat under your skin, epicardial fat is metabolically active and sits in direct contact with the heart muscle, with no barrier separating the two.
This proximity matters. Epicardial fat acts as a local source of inflammatory molecules that seep into the heart’s atrial tissue, promoting the kind of scarring and fibrosis that sustain AF.7PubMed Central. Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation Even more concerning, epicardial fat can physically infiltrate the atrial muscle, inserting itself between muscle fibers in a way that disrupts the electrical signals passing through them. A comprehensive review of the mechanisms linking obesity and AF confirmed that this combination of inflammation, fibrosis, and fat infiltration creates a self-reinforcing substrate: the more epicardial fat accumulates, the more the atria remodel in ways that perpetuate both AF and further fat deposition.8PubMed Central. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance
What makes epicardial fat particularly frustrating is that it doesn’t always track neatly with overall body weight. Some people with a normal BMI carry a disproportionate amount of epicardial fat, while some overweight individuals carry relatively little. This helps explain why AF sometimes develops in people who don’t look overweight, and why weight loss helps some AF patients more dramatically than others. The epicardial depot is the one that matters most for the heart, and it’s not something you can assess just by stepping on a scale.
Why Weight Loss Has an Outsized Effect on AF
If the relationship between weight and AF were simply one of shared risk factors, you’d expect weight loss to produce modest improvements. What actually happens is more dramatic. The LEGACY study, which followed an AF cohort over several years, found that patients who lost ten percent or more of their body weight had a six-fold greater probability of remaining free from arrhythmia compared with those who lost less or gained weight.9PubMed. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY) That’s a striking effect for a lifestyle intervention, on par with or better than many procedural and pharmaceutical treatments. Symptom severity and overall AF burden both dropped substantially in the group that achieved sustained weight loss.
The study also flagged an important nuance: weight fluctuation was independently harmful. People who yo-yo’d, losing and regaining weight repeatedly, did worse than those whose weight was stable, even if the stable group was heavier overall. This suggests that the metabolic and inflammatory disruption of repeated cycling may be even more damaging to atrial tissue than carrying excess weight steadily. For patients hoping to break the AF-weight feedback loop, the message is that gradual, sustained weight loss matters more than rapid dramatic changes.
Current expert guidance for AF management places weight loss and lifestyle modification at the top of the treatment hierarchy, ahead of even ablation in some frameworks. Recommendations include losing ten percent of body weight if obese, adopting a largely plant-based diet, incorporating moderate exercise, keeping blood pressure controlled, managing sleep disorders, and addressing anxiety and depression.10PubMed Central. Beyond Ablation in Atrial Fibrillation: 10 Steps to Better Control This comprehensive approach reflects the reality that AF is rarely just an electrical problem. It’s a condition embedded in a web of metabolic, inflammatory, and structural factors, and addressing the web produces results that a single-target intervention cannot.
When the Gain Isn’t Fat
Not all weight gain in AF patients comes from actual increases in body fat, and distinguishing between fat gain and fluid accumulation matters because the treatments are completely different. Fluid-related weight gain tends to come on faster, sometimes a kilogram or more in a single day, and it responds to adjustments in diuretic dosing, sodium restriction, and improved heart rate or rhythm control. Fat-related weight gain is slower, building over weeks and months, and it calls for the lifestyle and medication review described earlier.
A practical way to tell the difference at home is to weigh yourself every morning after using the bathroom and before eating. Rapid day-to-day swings of more than a pound or two almost always reflect fluid. A slow upward drift over weeks is more likely fat. Many heart failure management programs set a threshold, often two to three pounds in a day or five pounds in a week, at which patients should contact their care team. If you have AF and are gaining weight, adopting this habit can help you and your doctor figure out which pathway to target.
GLP-1 Receptor Agonists and Epicardial Fat
An emerging line of research that has generated significant interest involves GLP-1 receptor agonists, the same class of drugs that includes semaglutide and liraglutide. These medications, initially developed for type 2 diabetes and now widely used for weight management, appear to have effects on the heart’s fat deposits that go beyond simple calorie reduction.
Preclinical and early clinical studies suggest that GLP-1 receptor agonists can reduce the volume and thickness of epicardial adipose tissue to a degree that may exceed what you’d expect from the overall weight loss alone.11PubMed Central. Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists Beyond shrinking the fat pad, these drugs appear to dampen the inflammation and fibrosis that epicardial fat drives, and they may even reduce the abnormal electrical firing from the pulmonary veins that triggers many AF episodes. If confirmed in larger trials, this would make GLP-1 receptor agonists a treatment that simultaneously addresses the metabolic, inflammatory, and electrical components of the AF-obesity cycle.
This research is still in relatively early stages, and no major cardiology guideline yet recommends GLP-1 receptor agonists specifically for AF. But the biological logic is compelling: if epicardial fat is a key driver of AF, and these drugs preferentially shrink epicardial fat while also reducing systemic inflammation, they could become an important part of the toolkit. For AF patients who are already struggling with weight gain from beta-blockers or inactivity, a medication that addresses weight and the heart’s fat deposits simultaneously represents a genuinely different approach from anything currently available.
Sleep, Stress, and the Hidden Contributors
The weight gain associated with AF doesn’t happen in a vacuum. AF disrupts sleep, both directly through nighttime episodes and indirectly through the anxiety that accompanies a chronic heart condition. Poor sleep raises cortisol, increases appetite, promotes insulin resistance, and reduces motivation to exercise. Each of these effects independently promotes weight gain, and together they can be formidable.
Stress and depression follow a similar pattern. A diagnosis of AF is psychologically burdensome. Many patients describe constant awareness of their heartbeat, hypervigilance about physical symptoms, and worry about stroke risk. Chronic stress drives comfort eating, disrupts hormone regulation, and depletes the executive function you need to maintain healthy habits. Depression, which is more common in AF patients than in the general population, further reduces physical activity and can trigger appetite changes in both directions, though weight gain is the more common outcome.
These contributors rarely appear on a list of “why AF causes weight gain” because they’re not specific to AF. But they’re amplified by it. A person who sleeps poorly because of nighttime palpitations, avoids the gym because exercise triggers anxiety, takes a beta-blocker that slows their metabolism, and copes with the stress of a chronic diagnosis through food is dealing with four separate drivers of weight gain at once. Treating any one of them in isolation produces limited results. Addressing all of them together, which requires awareness that the problem is multi-layered, is where real progress happens.
If you’re managing AF and have noticed the scale climbing, the question worth asking isn’t just “why is this happening” but “which of these pathways is contributing the most for me right now?” The answer shapes what to do about it: talk to your prescriber about medication alternatives, get cleared for structured exercise, monitor for fluid retention, or address the sleep and psychological factors that may be quietly fueling the cycle.